I read an article about a new blood test developed for the diagnosis of Parkinson's disease that could make predictions even seven years before the development of symptoms. Having witnessed its debilitating effects on a family member, the potential for early detection feels tremendous. What is striking here is the fact that something as simple as a blood test, empowered with artificial intelligence, can help in foreseeing the disease much before its occurrence.
Sourcing
It is a progressive nervous system disorder whereby it always commences with slight shaking. Parkinson's disease can cause drastic interference with memory, balance, posture, mobility, and speech over time. Knowing that over 10 million people worldwide live with this condition, the potential of this new test hits even harder. At present, there is no cure for it, and treatments are basically oriented toward alleviating the symptoms using dopamine therapy. Such a forecast means that patients start receiving help only when they have begun suffering from the most debilitating effects of the disease.
Scientists in a group from University College London and University Medical Center Goettingen developed this new blood test. An algorithm enabled by artificial intelligence was used to analyze blood samples based on eight specific blood-based biomarkers that are commonly changed in people living with Parkinson's.
In a trial involving 72 participants with Rapid Eye Movement Behavior Disorder—a condition in which people act out their dreams—this AI was able to identify a Parkinson's-like profile in 79% of the cases.
This means it spotted those likely to come down with the disease, thus allowing for very early intervention.
The researchers were interested in iRBD in particular because 75–80% of those with the disorder went on to develop synucleinopathy—a brain disorder associated with the accumulation of the abnormal alpha-synuclein protein associated with Parkinson's. This team, through machine learning, was able to predict the onset of Parkinson's disease up to seven years in advance for 16 subjects. This is quite an achievement in that treatment strategies could now be targeted at protecting the dopamine-producing brain cells, slowing and even stopping the progress of the disease.
According to Dr. Kevin Mills, a senior research author, it is essential to diagnose patients before they have any symptoms. Once the brain cells are lost, they can never regrow, and thus, the protection of already existing ones is of considerable importance. Under the new criteria, identifying potential Parkinson's patients years in advance could mean treating them with experimental drug therapies far earlier—to possibly alter the course of a disease.
Another vital scientist, Dr. Michael Bartl, meanwhile commented that, despite having diagnosed the disease in itself, it had also identified the markers that were clearly connected to inflammation and the breakdown of nonfunctional proteins; these markers may thus be used as the object of effective remedies, making the future management of Parkinson's more plausible.
This discovery is, to me, a beacon of hope. The potential of being able to detect a disease that early will alter so many lives. Early detection itself means people could begin treatment before suffering through the sometimes terrible symptoms that usually correlate with a diminished level of life. It opens the door to preventive strategies that may delay or halt the progress of the disease.
Reading about such advancements makes me very hopeful. It really shows how far medical research has gone and how technology, more so, artificial intelligence is now playing a very vital role in healthcare. In the same breath, this makes me reflect on the future and its possibilities for those at risk of Parkinson's.